Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells

Cancer Research

Volumn 69, Issue 22, 2009, Pages 8752-8760

  Ueki, Tomomi ^a,b   Park, Jae Hyun ^a   Nishidate, Toshihiko ^a,b   Kijima, Kyoko ^a   Hirata, Koichi ^b   Nakamura, Yusuke ^a   Katagiri, Toyomasa ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; BRCA1 PROTEIN; CYSTEINE; SMALL INTERFERING RNA; UBIQUITIN CONJUGATING ENZYME E2;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UBIQUITINATION;

BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 72249103199     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1809     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;51:74-108.
2. Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: what we know and what we need. Nat Med 2001;7:552-556
3. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71. (Pubitemid 24345325)
4. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-676
5. Petricoin EF III, Hackett JL, Lesko LJ, et al. Medical applications of microarray technologies: a regulatory science perspective. Nat Genet 2002;32 Suppl:474-479
6. Nishidate T, Katagiri T, Lin ML, et al. Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol 2004;25:797-819.
7. Park JH, Lin ML, Nishidate T, Nakamura Y, Katagiri T. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen having an oncogenic activity in breast cancer. Cancer Res 2006;66:9186-9195
8. Shimo A, Nishidate T, Ohta T, Fukuda M, Nakamura Y, Katagiri T. Elevated expression of PRC1, protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Sci 2007;98:174-181 (Pubitemid 44941869)
9. Lin ML, Park JH, Nishidate T, Nakamura Y, Katagiri T. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of Bcl-2 family. Breast Cancer Res 2007;9:R17. (Pubitemid 350215144)
10. Shimo A, Tanikawa C, Nishidate T, et al. Involvement of kinesin family member 2C/mitotic centromereassociated kinesin overexpression in mammary carcinogenesis. Cancer Sci 2008;99:62-70. (Pubitemid 350239032)
11. Ueki T, Nishidate T, Park JH, et al. Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells. Oncogene 2008;27:5672-5683
12. Iyer VR, Eisen MB, Ross DT, et al. The transcriptional program in the response of human fibroblasts to serum. Science 1999;283:83-87
13. Machida YJ, Machida Y, Chen Y, et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell 2006;23:589-596 (Pubitemid 44205488)
14. Alpi A, Langevin F, Mosedale G, Machida YJ, Dutta A, Patel KJ. UBE2T, the Fanconi anemia core complex, and FANCD2 are recruited independently to chromatin: a basis for the regulation of FANCD2 monoubiquitination. Mol Cell Biol 2007;27:8421-8430
15. Americal Type Culture Collection (ATCC). Cell line verification test recommendations; ATCC recommends cell line verification tests and guidelines for publishing. ATCC Technical Bulletin 2007;no. 8.
16. Katagiri T, Ozaki K, Fujiwara T, et al. Cloning, expression and chromosome mapping of adducin-like 70 (ADDL), a human cDNA highly homologous to human erythrocyte adducin. Cytogenet Cell Genet 1996;74:90-95 (Pubitemid 26336495)
17. Choudhury AD, Xu H, Baer R. Ubiquitination and proteasomal degradation of the BRCA1 tumor suppressor is regulated during cell cycle progression. J Biol Chem 2004;279:33909-33918
18. Suzuki C, Murakami G, Fukuchi M, et al. Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J Biol Chem 2002; 277:39919-39925
19. Sengupta S, Robles AI, Linke SP, et al. Functional interaction between BLM helicase and 53BP1 in a Chk1- mediated pathway during S-phase arrest. J Cell Biol 2004;166:801-813 (Pubitemid 39249832)
20. Shimokawa T, Furukawa Y, Sakai M, et al. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the β-catenin/T-cell factor complex. Cancer Res 2003;63:6116-6120 (Pubitemid 37255147)
21. Hashizume R, Fukuda M, Maeda I, et al. The RING heterodimer BRCA1-1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 2001;276:14537-14540
22. Baer R, Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr Opin Genet Dev 2002;12:86-91. (Pubitemid 34094995)
23. Brzovic PS. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci U S A 2003;100:5646-5651
24. Sato K, Hayami R, Wu W, et al. Nucleophosmin/B23 is a candidate substrate for the BRCA1-1 ubiquitin ligase. J Biol Chem 2004;279:30919-30922 (Pubitemid 39037748)
25. Eakin CM,Maccoss MJ, Finney GL, Klevit RE. Estrogen receptor α is a putative substrate for the BRCA1 ubiquitin ligase. Proc Natl Acad Sci U S A 2007;104:5794-5799
26. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-819
27. Elstrodt F, Hollestelle A, Nagel JH, et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 2006; 66:41-45 (Pubitemid 43166006)
28. Chen A, Kleiman FE, Manley JL, Ouchi T, Pan ZQ. Autoubiquitination of the BRCA1-1 RING ubiquitin ligase. J Biol Chem 2002;277:22085-22092 (Pubitemid 34952363)
29. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299
30. Urano T, Saito T, Tsukui T, et al. Efptargets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 2002;417:871-875
31. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685
32. Arvand A, Bastians H, Welford SM, Thompson AD, Ruderman JV, Denny CT. EWS/FLI1 upregulates mE2- C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction. Oncogene 1998;17: 2039-2045 (Pubitemid 28499330)
33. Yang Y, Kitagaki J, Wang H, Hou DX, Perantoni AO. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci 2009;100:24-28
34. Yang Y, Kitagaki J, Dai RM, et al. Inhibitors of ubiquitin- activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 2007;67:9472-9481
35. Okamoto Y, Ozaki T, Miyazaki K, AoyamaM,Miyazaki M, Nakagawara A. UbcH10 is the cancer-related E2 ubiquitin- conjugating enzyme. Cancer Res 2003;63:4167-4173
36. Berlingieri MT, Pallante P, Guida M, et al. UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene 2007;26:2136-2140 (Pubitemid 46514746)
37. Berlingieri MT, Pallante P, Sboner A, et al. UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer 2007;43:2729-2735 (Pubitemid 350161847)
38. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005;11:2625-2636 (Pubitemid 40569463)
39. Kikuchi T, Daigo Y, Katagiri T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymphnode metastasis and sensitivity to anti-cancer drugs. Oncogene 2003;22:2192-2205
40. Ashida S, Nakagawa H, Katagiri T, et al. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide geneexpression profiles of prostate cancers and PINs. Cancer Res 2004;64:5963-5972
41. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006;25:5854-5863
42. Fang S, Weissman AM. A field guide to ubiquitylation. Cell Mol Life Sci 2004;61:1546-1561
43. Furuta S, Jiang X, Gu B, Cheng E, Chen PL, Lee WH. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc Natl Acad Sci U S A 2005;102:9176-9181